Clinical trial · Interventional
Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-cachexia in Advanced Cancer Patients.
Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-cachexia in Advanced Cancer Patients: A Randomized, Double-Blind Trail.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study was 8 weeks randomized, double-blind trail to assess the effect of mirtazapine versus megestrol acetate in treatment of anorexia-cachexia in advanced cancer patients in 80 patients. Participants were assessed at baseline, 4 weeks and 8 weeks. Subject were randomized to receive either mirtazapine 15 mg tablet daily or megestrol acetate 160 mg tablet daily for 8 weeks. The primary outcome was the measure of FAACT(A/C) score and the secondary measure includes weight, BMI, quality of life and evaluate adverse effects.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anorexia | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Megestrol Acetate | Drug | Megestrol | ALIAS |
| Mirtazapine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Mirtazapine
- description
- Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night. This group will consist of 40 patients with anorexia in advanced cancer patients.
- interventionNames
- Drug: Mirtazapine
- type
- ACTIVE_COMPARATOR
- label
- Megestrol Acetate
- description
- Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night This group will consist of 40 patients with anorexia in advanced cancer patients.
- interventionNames
- Drug: Megestrol Acetate
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged ≥ 18 years, with a histologically diagnosed advanced-stage tumor at any site. * Assumptive or documented loss of \>5% of pre-illness or ideal body weight (body mass index) in the previous 3 months. * Patients could be receiving concomitant chemotherapy, radiotherapy and/or palliative supportive care. * Patients ECOG Performance Status 0-3. Exclusion Criteria: * Patients with a mechanical obstruction to feeding. * Patients with high doses of corticosteroids. * Patients with clinically bulky ascites and generalized edema. * Patients with inability to take oral medications. * History of uncontrolled diabetes mellitus and hypertension.
References
Publications (0)
Data not yet available